
## Leslie L Popplewell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6423761/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 504-512.	0.4	17
2	Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B ell Lymphoma: Results from a Phase 1b Study. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e443-e451.	0.4	10
3	Long-Term Follow-Up of Multiple Myeloma Patients Treated with Tandem Autologous Transplantation Following Melphalan and Upon Recovery, Total Marrow Irradiation. Transplantation and Cellular Therapy, 2022, 28, 367.e1-367.e9.	1.2	4
4	Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma. Blood, 2022, 140, 2697-2708.	1.4	15
5	The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma. Cancer Immunology Research, 2021, 9, 75-88.	3.4	24
6	Double-hit Signature with <i>TP53</i> Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP. Clinical Cancer Research, 2021, 27, 1671-1680.	7.0	24
7	Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma*. Leukemia and Lymphoma, 2021, 62, 2094-2106.	1.3	7
8	CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. Blood Advances, 2021, 5, 4059-4063.	5.2	62
9	Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas. Blood, 2021, 138, 133-133.	1.4	13
10	A Phase I Trial of PI3Kαδ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL). Blood, 2021, 138, 3558-3558.	1.4	3
11	Pembrolizumab Plus Vorinostat Induces Responses in Patients with Hodgkin Lymphoma Who Are Refractory to Prior PD-1 Blockade. Blood, 2021, 138, 234-234.	1.4	5
12	A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL). Blood, 2021, 138, 2436-2436.	1.4	5
13	Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study. Blood, 2021, 138, 131-131.	1.4	8
14	Results from a Phase 1 Study to Evaluate a Memory-Enriched CD19-Specific CAR T Cell Platform in Adult Patients with CD19+ B-Cell Non-Hodgkin Lymphoma (B-NHL). Blood, 2021, 138, 2836-2836.	1.4	1
15	ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing. Blood, 2021, 138, 649-649.	1.4	22
16	A Randomized Open Label Pilot Study of <i>Clostridium Butyricum</i> Miyairi 588 (CBM588) in Recipients of Allogeneic Hematopoietic Cell Transplantation. Blood, 2021, 138, 334-334.	1.4	1
17	Sarcopenia Is a Clinically Relevant and Independent Predictor of Health Outcomes after Chimeric Antigen Receptor T-Cell Therapy for Lymphoma. Blood, 2021, 138, 2502-2502.	1.4	6
18	Atezolizumab Combined with Immunogenic Salvage Chemoimmunotherapy (R-GemOx+Atezo) in Patients with Transformed Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 1407-1407.	1.4	1

LESLIE L POPPLEWELL

#	Article	IF	CITATIONS
19	Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 749-756.e1.	0.4	4
20	Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies. Leukemia and Lymphoma, 2020, 61, 309-317.	1.3	22
21	Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma. Clinical Cancer Research, 2020, 26, 1034-1044.	7.0	48
22	First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas. Clinical Cancer Research, 2020, 26, 2524-2534.	7.0	40
23	Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma. Blood, 2020, 136, 27-28.	1.4	1
24	Incidence and Causes of Prolonged Hematologic Toxicity after Chimeric Antigen Receptor T Cell Therapy: A City of Hope (COH) Experience. Blood, 2020, 136, 40-41.	1.4	2
25	A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma. Clinical Cancer Research, 2019, 25, 7004-7013.	7.0	32
26	Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis. Biology of Blood and Marrow Transplantation, 2019, 25, 287-292.	2.0	6
27	Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma. Blood, 2019, 133, 306-318.	1.4	26
28	Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies. Blood, 2019, 134, 5329-5329.	1.4	12
29	PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma. Blood, 2019, 134, 239-239.	1.4	31
30	Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma. Blood, 2019, 134, 759-759.	1.4	18
31	Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas. Blood, 2019, 134, 4023-4023.	1.4	6
32	CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma. Blood, 2019, 134, 4075-4075.	1.4	10
33	Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center. Blood, 2019, 134, 4623-4623.	1.4	0
34	Outcomes of Patients with T-Lymphoblastic Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center. Blood, 2019, 134, 5729-5729.	1.4	1
35	Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). Biology of Blood and Marrow Transplantation, 2018, 24, 700-707.	2.0	16
36	A phase I/II trial of vorinostat (SAHA) in combination with rituximabâ€CHOP in patients with newly diagnosed advanced stage diffuse large Bâ€cell lymphoma (DLBCL): SWOG S0806. American Journal of Hematology, 2018, 93, 486-493.	4.1	38

LESLIE L POPPLEWELL

#	Article	IF	CITATIONS
37	Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biology of Blood and Marrow Transplantation, 2018, 24, 514-520.	2.0	31
38	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. Lancet Haematology,the, 2018, 5, e543-e553.	4.6	53
39	Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. Journal of Hematology and Oncology, 2018, 11, 87.	17.0	12
40	Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma. Blood, 2018, 132, 1636-1636.	1.4	5
41	The Cerebroventricular Environment Reprograms Locally Infused CAR T Cells for Superior Activity Against Both CNS and Systemic B Cell Lymphoma. Blood, 2018, 132, 965-965.	1.4	2
42	CD19-CAR Therapy Using Naive/Memory or Central Memory T Cells Integrated into the Autologous Stem Cell Transplant Regimen for Patients with B-NHL. Blood, 2018, 132, 610-610.	1.4	9
43	Muscle Depletion Is an Important and Clinically Relevant Predictor of Outcomes after Autologous Hematopoietic Cell Transplantation. Blood, 2018, 132, 620-620.	1.4	0
44	Comparison of Efficacy and Safety of Biosimilar CT-P10 to Rituximab in Patients with Previously Untreated Low Tumor Burden Follicular Lymphoma (LTBFL): A Randomized Phase III Study. Blood, 2018, 132, 1596-1596.	1.4	1
45	Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology. Biology of Blood and Marrow Transplantation, 2017, 23, 922-929.	2.0	9
46	Are Disagreements in Caregiver and Patient Assessment of Patient Health Associated with Increased Caregiver Burden in Caregivers of Older Adults with Cancer?. Oncologist, 2017, 22, 1383-1391.	3.7	29
47	Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. Biology of Blood and Marrow Transplantation, 2017, 23, 1861-1869.	2.0	19
48	Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. Journal of Clinical Oncology, 2017, 35, 24-31.	1.6	152
49	Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma. Blood, 2017, 130, 738-738.	1.4	5
50	Reliability, Validity, and Feasibility of a Computer-Based Geriatric Assessment for Older Adults With Cancer. Journal of Oncology Practice, 2016, 12, e1025-e1034.	2.5	83
51	Activity of the oral mitogenâ€activated protein kinase kinase inhibitor trametinib in <scp><i>RAS</i></scp> â€mutant relapsed or refractory myeloid malignancies. Cancer, 2016, 122, 1871-1879.	4.1	113
52	Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. Clinical Cancer Research, 2016, 22, 868-876.	7.0	262
53	Challenges in the implementation of survivorship care plans in an NCI-designated cancer center Journal of Clinical Oncology, 2016, 34, 68-68.	1.6	1
54	New Therapeutic Approach for Central Nervous System Lymphoma By Intracerebroventricular Delivery of CD19CAR T Cells. Blood, 2016, 128, 2161-2161.	1.4	0

#	Article	IF	CITATIONS
55	Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2015, 21, 2136-2140.	2.0	131
56	Multicenter Phase 1b Dose-Escalation Study of Ibrutinib and Lenalidomide Combined with Dose-Adjusted EPOCH-R in Patients with Relapsed/Refractory DLBCL. Blood, 2015, 126, 1527-1527.	1.4	12
57	Phase I Studies of Cellular Immunotherapy Using Central Memory Derived-CD19-Specific T Cells Following Autologous Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma. Blood, 2015, 126, 930-930.	1.4	2
58	Results from a Phase 1 Study and Expanded Cohort of an Interrupted Dosing Schedule of the Aurora Kinase a Inhibitor MLN8237 Combined with Vorinostat in Lymphoid Malignancies. Blood, 2015, 126, 2731-2731.	1.4	0
59	Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1183-1189.	2.0	89
60	Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2014, 20, 1864-1868.	2.0	56
61	Brentuximab Vedotin Improves HCT-CI, CR Status, and Peri-Transplant Toxicity In Patients With Relapsed/Refractory Hodgkin Lymphoma Heading To RIC Allo-HCT. Blood, 2013, 122, 3374-3374.	1.4	3
62	Romidepsin Is Effective and Well-Tolerated In Patients ≥ 60 Years Old With Relapsed Or Refractory Peripheral T-Cell Lymphoma (PTCL): Analysis From Phase 2 Trials. Blood, 2013, 122, 4385-4385.	1.4	2
63	Final Results Of A Phase 2 Study Of Vorinostat Plus Rituximab In Newly Diagnosed, Relapsed Or Refractory Indolent Non-Hodgkin's Lymphoma. Blood, 2013, 122, 4398-4398.	1.4	1
64	Immunologic and Clinical Responses To a CD20-Targeted Immunocytokine, DI-Leu16-IL2, In Relapsed Non-Hodgkin Lymphoma. Blood, 2013, 122, 1808-1808.	1.4	0
65	Phase I-II Trial of Tandem Autologous Transplantation with Melphalan Followed by Total Marrow Irradiation Ablative Therapy in Patients with Responding or Stable Mutiple Myeloma Blood, 2012, 120, 3151-3151.	1.4	1
66	Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute Leukemia. Blood, 2012, 120, 675-675.	1.4	12
67	Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease. Blood, 2012, 120, 677-677.	1.4	16
68	A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. Blood, 2012, 120, 3698-3698.	1.4	0
69	Pillar-1: Multicenter Phase 2 Study of Everolimus for Patients with Mantle Cell Lymphoma Who Are Refractory or Intolerant to Bortezomib Blood, 2012, 120, 2751-2751.	1.4	Ο
70	Conditional Survival and Cause-Specific Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Hematologic Malignancy Over Three Decades. Blood, 2012, 120, 606-606.	1.4	0
71	Primary anaplastic large-cell lymphoma associated with breast implants. Leukemia and Lymphoma, 2011, 52, 1481-1487.	1.3	55
72	Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma. Blood, 2011, 118, 664-664.	1.4	6

LESLIE L POPPLEWELL

#	Article	IF	CITATIONS
73	Pralatrexate Is An Effective Treatment for Heavily Pretreated Patients with Relapsed/Refractory Transformed Mycosis Fungoides (tMF). Blood, 2010, 116, 1762-1762.	1.4	8
74	High Rate of Complete Remission (CR) and Upgraded Response with Weekly Maintenance Bortezomib Post Single Autologous Peripheral Stem Cell Transplant (PSCT) In Patients with Multiple Myeloma. Results of a Phase II Prospective Study. Blood, 2010, 116, 2399-2399.	1.4	1
75	PILLAR-1: Preliminary Results of a Phase II Study of mTOR Inhibitor Everolimus In Patients with Mantle Cell Lymphoma (MCL) Who Are Refractory or Intolerant to Bortezomib. Blood, 2010, 116, 3963-3963.	1.4	3
76	Pralatrexate Is Effective as Second-Line Treatment Following Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) Failure In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL). Blood, 2010, 116, 4882-4882.	1.4	6
77	Cause-Specific Conditional Survival In 2603 Consecutive Patients Undergoing Autologous Hematopoietic Cell Transplantation (aHCT) Over a 20-Year Period. Blood, 2010, 116, 933-933.	1.4	0
78	Early Mortality After Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies Performed In the Recent Era. Blood, 2010, 116, 902-902.	1.4	0
79	Final Report of a Phase I Study of Clofarabine Plus High Dose Melphalan as a Conditioning Regimen for Allogeneic Transplantation. Blood, 2010, 116, 528-528.	1.4	1
80	A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. Blood, 2010, 116, 3957-3957.	1.4	2
81	A Retrospective Analysis of Using Pre-Transplant Functional FDG-PET to Predict for Relapse and Survival in Relapsed Hodgkin Lymphoma (HL) Patients Undergoing Autologous Hematopoietic Cell Transplantation (AHCT) Blood, 2009, 114, 1225-1225.	1.4	Ο
82	Y90 Plus High Dose BEAM with Autologous Stem Cell Transplantation for Chemorefractory Non Hodgkin Lymphoma Blood, 2009, 114, 3423-3423.	1.4	0
83	Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Can Induce Durable Remission in Heavily Pretreated Relapsed Hodgkin Lymphoma. (HL) Blood, 2009, 114, 1192-1192.	1.4	Ο
84	A Phase II Study of Sequential Velcade/Thalidomide/ Dexamethasone (VTD) as Maintenance Therapy Post Single Autologous Peripheral Stem Cell (PSCT) in Patients with Multiple Myeloma Blood, 2009, 114, 3403-3403.	1.4	0
85	Phase I Study of Bortezomib in Combination with Gemcitabine in Relapsed/Refractory Intermediate Grade B-Cell and Mantle Cell Non-Hodgkin's Lymphoma Blood, 2009, 114, 1682-1682.	1.4	Ο
86	Yttrium 90 Plus High Dose BEAM Conditioning with Autologous Stem Cell Transplantation (ASCT); Effects of Prior Rituximab and Outcome of Poor Risk Non Hodgkin Lymphoma (NHL) Blood, 2009, 114, 2323-2323.	1.4	4
87	90.y-Ibritumomab Tiuxetan (Zevalin®) May Enhance Anti-Lymphoma Effect of Reduced-Intensity Fludarabine and Melphalan Regimen in Patients with Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Blood, 2009, 114, 3357-3357.	1.4	0
88	Longitudinal Trends in Peripheral Blood Parameters Predict Development of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia (t-MDS/ AML) after Autologous Transplantation for Lymphoma Blood, 2008, 112, 2133-2133.	1.4	0
89	Reduced Intensity (RI) Allogeneic Hematopoietic Cell Transplantation (HCT) Improves Outcomes for Older (≥ 60 Yrs) Patients (Pts) with Acute Myeloid Leukemia (AML) Blood, 2007, 110, 1089-1089.	1.4	0
90	Similar Outcome with Early Reduced Intensity Conditioning (RIC) Allogeneic Transplant to Autologous-Non-Myeloablative Allogeneic (Auto-Allo) Transplant in Patients with Multiple Myeloma Blood, 2007, 110, 3030-3030.	1.4	0

#	Article	IF	CITATIONS
91	Large Granular Lymphocytosis Following Transplantation: Institutional Experience over a 10-Year Period at City of Hope Blood, 2005, 106, 2024-2024.	1.4	0
92	Primary Anaplastic Large Cell Lymphoma of the Breast Occurring in Patients with Silicone Breast Implants Blood, 2004, 104, 4563-4563.	1.4	2
93	Autologous vs Allogeneic Cell Transplantation for Mantle Cell Lymphoma (MCL): Outcomes over a 10-Year Period at City of Hope Blood, 2004, 104, 894-894.	1.4	5